Seizure Prophylaxis in Traumatic Brain Injury
Routine seizure prophylaxis with antiepileptic drugs (AEDs) is NOT recommended for patients with traumatic brain injury, as the evidence shows no significant benefit in preventing early or delayed post-traumatic seizures, and may actually worsen neurological outcomes. 1
Evidence-Based Recommendation
The 2018 European guideline provides a Grade 2- recommendation (strong agreement) against using antiepileptic drugs for primary prevention of post-traumatic seizures. 1 This is supported by analysis of 11 clinical trials involving over 2,700 patients that found:
- No significant effect of AEDs in preventing early seizures (within 7 days)
- No significant effect in preventing delayed seizures (after 7 days)
- Increased side effects with phenytoin use
- Potential worsening of neurological outcomes with AED prophylaxis 1
The 2024 Neurocritical Care Society guideline reinforces this, stating: "We suggest that ASM or no ASM may be used in patients hospitalized with moderate-severe TBI (weak recommendation, low quality of evidence)." 2
Understanding the Seizure Risk
The baseline risk of early clinical seizures is relatively low:
- 2.2% overall incidence in first 7 days
- 11.9% in severe TBI patients within the first year
- 2.1% delayed seizure rate after 7 days 1
A 2024 meta-analysis found the absolute risk reduction with prophylaxis was only 0.6% (number needed to treat = 167 patients to prevent one seizure). 3
When to Consider Prophylaxis (Selective Use Only)
Prophylaxis may be considered in specific high-risk scenarios:
High-Risk Features:
- Brain contusion
- Acute subdural hematoma
- Skull fracture
- Loss of consciousness or amnesia >24 hours
- Age >65 years
- Craniectomy (identified as independent risk factor) 1
- Chronic subdural hematoma
- Prior history of epilepsy 1
If Prophylaxis is Used:
Agent Selection:
- Levetiracetam is preferred over phenytoin/fosphenytoin due to better tolerance and fewer side effects 1, 2
- Phenytoin has demonstrated increased adverse events and potential for worse neurological outcomes 1, 4
Duration:
- ≤7 days maximum (weak recommendation, low quality evidence) 2
- Longer duration shows no additional benefit and is associated with worse cognitive outcomes and more adverse events 2
Critical Pitfalls to Avoid
Do not use routine prophylaxis - A 2018 prospective study comparing centers with and without routine prophylaxis found no difference in seizure rates (3.7% vs 2.8%, p=0.573) 5
Phenytoin may harm functional recovery - A 2014 study showed patients receiving phenytoin prophylaxis had significantly longer hospital stays (36 vs 25 days, p=0.04) and worse Glasgow Outcome Scale scores (2.9 vs 3.4, p<0.01) compared to no prophylaxis 4
Avoid prolonged use - No evidence supports continuation beyond 7 days, and cognitive impairment increases with longer duration 2
Moderate TBI warrants closer scrutiny - Patients with moderate TBI (GCS 9-12) with intracranial hemorrhage show higher seizure rates (15.2% confirmed seizures) compared to mild TBI (3.6%), suggesting this subgroup may benefit from prophylaxis, though prospective trials are needed 6
Algorithm for Decision-Making
Step 1: Assess TBI severity and imaging findings
- Mild TBI (GCS 13-15) with ICH → Generally no prophylaxis
- Moderate TBI (GCS 9-12) with ICH → Consider prophylaxis (15% seizure rate)
- Severe TBI (GCS <9) → Consider prophylaxis only if high-risk features present
Step 2: Identify high-risk features (see list above)
- If ≥2 high-risk features present → Consider prophylaxis
- If isolated TBI without high-risk features → No prophylaxis
Step 3: If prophylaxis chosen:
- Use levetiracetam (not phenytoin)
- Duration: 7 days maximum
- Document clear stop date to prevent inappropriate continuation
Step 4: Monitor for clinical seizures (not routine EEG unless clinically indicated)
The evidence consistently demonstrates that the small potential benefit of seizure prophylaxis does not outweigh the risks of adverse effects and potential functional impairment in most TBI patients.